FDA denies approval of generic Lovenox

Novartis AG and biotechnology firm Momenta Pharmaceuticals' generic version of anti-clotting drug Lovenox has been rejected by the FDA due to concerns about the treatment's effect on the immune system. Momenta executives said they would work with the FDA to address their concerns.

View Full Article in:

Boston Globe (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN